TNFRSF9 and acute myeloid leukemia: In a phase I clinical trial, 12 patients with refractory acute myeloid leukemia were administrated with expanded high dose of NK-cells (106-107/kg/dose) using membrane-bound IL-21 and CD137 ligand expressed on K562.